US67022C2052 - ADR
NUCANA PLC-ADR
NASDAQ:NCNA (4/26/2024, 7:06:03 PM)
4
+0.19 (+4.99%)
NuCana Plc is a clinical stage biopharmaceutical company. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The firm is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
NUCANA PLC-ADR
Lochside House, 3 Lochside Way
Edinburgh EH12 9DT
P: 4401313571111
CEO: Hugh Griffith
Employees: 28
Website: https://www.nucana.com/
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Let's have a look at the gap up and gap down stocks in today's session.
NUC-7738 Reprograms Cancer Cell Lipid Metabolism to Make Tumors Less Aggressive and Promote Cancer Cell Death NUC-7738 Alters Ribosome Biogenesis and the...
Here you can normally see the latest stock twits on NCNA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: